Human Growth Hormone Stimulates Proteinase Activities of Rabbit Bone Cells via IGF-I

2000 ◽  
Vol 268 (3) ◽  
pp. 875-881 ◽  
Author(s):  
Rousselle Anne-Valérie ◽  
Damiens Christelle ◽  
Fortun Yannick ◽  
Passuti Norbert ◽  
Padrines Marc ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Bone Cells ◽  
Human Growth ◽  
Igf I ◽  
Rabbit Bone

Human growth hormone effect on serum IGF-I and muscle function in poliomyelitis survivors

1994 ◽  
Vol 75 (8) ◽  
pp. 889-894 ◽  
Author(s):  
Krishan L. Gupta ◽  
Kaup R. Shetty ◽  
James C. Agre ◽  
Mary C. Cuisinier ◽  
Inge W. Rudman ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Muscle Function ◽  
Human Growth ◽  
Hormone Effect ◽  
Igf I

scholarly journals 20kDa Human Growth Hormone (20K hGH) Stimulates Insulin-Like Growth Factor-I (IGF-I) Gene Expression at Lower Concentrations than 22K hGH in hGH Receptor-Expressing Ba/F3 Cells

2000 ◽  
Vol 47 (SupplMarch) ◽  
pp. S37-S40 ◽  
Author(s):  
HIDEO YOSHIZATO ◽  
MINORU TANAKA ◽  
TAKAHIKO FUJIKAWA ◽  
YOSHIFUMI HIGASHIMOTO ◽  
AYAKO SHIMIZU ◽  
...  
Keyword(s):  
Gene Expression ◽  
Growth Hormone ◽  
Growth Factor ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf I ◽  
Growth Factor I ◽  
I Gene

Dose-dependent stimulatory effect of human growth hormone on the strength and collagen deposition of colonic anastomoses in the rat

1992 ◽  
Vol 126 (5) ◽  
pp. 438-443 ◽  
Author(s):  
Henrik Christensen ◽  
Allan Flyvbjerg
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Dry Weight ◽  
Preoperative Treatment ◽  
Collagen Deposition ◽  
Hydroxyproline Content ◽  
Colonic Anastomoses ◽  
Bursting Strength ◽  
Igf I

The effects of treatment with four different doses of biosynthetic human growth hormone (b-hGH; 0.125mg kg−1 d−1, 0.5mg kg−1 d−1, 2.0 mg kg−1 d−1, 8.0 mg kg−1 d−1) on the bursting strength and collagen deposition of rat colonic anastomoses were studied. Rats receiving 2.0mg and 8.0 mg b-hGH demonstrated increases in the pre- and postoperative body weights, and the bursting strength and hydroxyproline content of the anastomotic segments in these groups were significantly higher than controls on day 4 postoperatively. The serum levels of insulin-like growth factor I (IGF-I) were significantly higher than the controls after four days of preoperative treatment in the groups receiving 2.0 mg and 8.0 mg b-hGH, and postoperatively the IGF-I levels were significantly higher than those of the controls in the groups receiving 0.5 mg, 2.0 mg and 8.0 mg b-hGH per kg. Consequently, positive correlations were found between treatment doses of b-hGH and anastomotic defatted dry weight, hydroxyproline content and bursting strength of colonic anastomoses.

Studies on regulation of insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-4 production in human bone cells

1992 ◽  
Vol 127 (6) ◽  
pp. 555-564 ◽  
Author(s):  
Subburaman Mohan ◽  
Donna D Strong ◽  
Uta G Lempert ◽  
Florence Tremollieres ◽  
Jon E Wergedal ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Conditioned Medium ◽  
Cell Cultures ◽  
Bone Cells ◽  
Human Growth ◽  
Bone Cell ◽  
Human Bone ◽  
Human Bone Cell ◽  
Igf I ◽  
Igfbp 3

Previous studies have shown that the actions of IGF-II in bone are determined not only by its concentration, but also by the concentration of IGFBP-4 as well as other IGFBPs. In this study, we sought to determine by Western ligand blotting the effects of growth hormone, IGF-I and IGF-II on the production of IGFBP-3 and IGFBP-4 in TE89 human osteosarcoma cells and in untransformed normal human bone cells derived from rib. Human growth hormone at 10 μg/l decreased the amount of IGFBP-4 but had no effect on the IGFBP-3 level in the conditioned medium of low density cultures of TE89 cells and human bone cells derived from rib. Human growth hormone had no effect on IGFBP-3 or IGFBP-4 levels in the conditioned medium of high density human bone cell cultures. IGF-I and IGF-II, which increased human bone cell proliferation, decreased the level of IGFBP-4 (30% of control at 100 μg/l IGF-I and IGF-II) but increased the level of IGFBP-3 (3–10 fold at 100 μg/l IGF-I and IGF-II) after 48 h of treatment in the conditioned medium of both low and high density TE89 cell cultures. Similar changes in IGFBP-3 and IGFBP-4 levels were also seen in the conditioned medium of human bone cells derived from rib after treatment with IGF-I and IGF-II. Studies to determine the underlying molecular mechanisms by which IGF-II decreased the amount of IGFBP-4 in the conditioned medium revealed that IGF-II decreased the IGFBP-4 mRNA abundance and increased the IGFBP-3 mRNA abundance in human bone cells. Based on the above findings, we conclude that the production of both IGFBP-3 and IGFBP-4 is regulated in bone cells and that local and systemic agents may modulate the responsiveness of bone cells to IGFs by regulated secretion of IGFBP-3 and IGFBP-4.

Basal characteristics and first year responses to human growth hormone (GH) vary according to diagnostic criteria in children with non-acquired GH deficiency (naGHD): observations from a single center over a period of five decades

2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Michael B. Ranke ◽  
Roland Schweizer ◽  
Gerhard Binder
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Diagnostic Criteria ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Height Velocity ◽  
First Year ◽  
Insulin Like Growth Factor ◽  
Igf I ◽  
Igfbp 3

Abstract Background Children with non-acquired (na) growth hormone deficiency (GHD) diagnosed over decades in one center may provide perspective insight. Methods naGHD is divided into idiopathic GHD (IGHD), GHD of known cause (cGHD) and GHD neurosecretory dysfunction (NSD); time periods: <1988 (I); 1988–1997 (II); 1998–2007 (III); 2008–2015 (IV). Descriptive analyses were performed at diagnosis and during first year GH treatment. Results Patients (periods, N): I, 87; II, 141; III, 356; IV, 51. In cGHD (all), age, maximum GH, insulin-like growth factor-I (IGF-I), and insulin-like growth factor-binding protein-3 (IGFBP-3) (5.1 years, 3.6 μg/L, −5.3 standard deviation score [SDS], −3.7 SDS) were lower than in IGHD (all) (6.8 years 5.8 μg/L, −2.5 SDS, −1.0 SDS), but not height (−3.1 vs. −3.2 SDS). Characteristics of NSD were similar to that of IGHD. Patients with IGHD – not cGHD – diagnosed during 2008–2015 (IV) were the youngest with most severe GHD (maxGH, IGF-I, IGFBP-3), and first year height velocity (HV) and ∆ IGF-I (10.5 cm/year, 4.0 SDS) but not ∆ height SDS were the highest on recombinant human growth hormone (rhGH) (27 μg/kg/day). Conclusions Although during 1988–2007 patient characteristics were similar, the recently (>2008) stipulated more stringent diagnostic criteria – HV before testing, sex steroid priming, lower GH cut-off – have restricted diagnoses to more severe cases as they were observed before the rhGH era.

EFFECTS OF RECOMBINANT AND ENDOGENOUSLY PRODUCED HUMAN GROWTH HORMONE ON THE IGF I SYSTEM 1139

1997 ◽  
Vol 29 (Supplement) ◽  
pp. 200
Author(s):  
W. Schmidt ◽  
G. Brabant ◽  
S. Lison ◽  
T. M??nte
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Igf I
Sign in / Sign up

Export Citation Format

Share Document